论文部分内容阅读
心脏病发作后不论服用Cox-2 抑制剂,还是服用其他的非甾体类抗炎药物(NSAIDs),都会增加死亡危险,该结论是由丹麦哥本哈根 Bispebjierg大学的Gunnar Gislason 领导的一项试验中得出的。在研究中,入选患者是1995-2002年间有过第一次急性心脏病发作者,共 58 432人。经过调整年龄、性别和其他医疗状况,发现服用Cox-2抑制剂和NSAIDs的患者死亡危险相当高,危险比(以对照组的危险作为1)是:剂量超过200mg／日的塞来考昔(celecoxib,西乐葆, Celebrex)为4．24;超过25mg／日的罗非考昔(refecoxib,万络,Vioxx) 为5．03;超过100mg／日的双氯芬酸
The risk of dying, whether taking Cox-2 inhibitors or taking other non-steroidal anti-inflammatory drugs (NSAIDs) after a heart attack, increases the risk of death, a finding led by Gunnar Gislason of Bispebjierg University in Copenhagen, Denmark Out of In the study, the patients enrolled were the first to have had an acute heart attack between 1995 and 2002, for a total of 58,432 people. Patients adjusted for age, gender and other medical conditions were found to be at very high risk of death from taking Cox-2 inhibitors and NSAIDs. The hazard ratio (hazard ratio 1) in the control group was celecoxib at doses greater than 200 mg / day celecoxib, Celebrex) was 4.24; refecoxib at more than 25 mg / day was 5.03; diclofenac at more than 100 mg / day